IL157075A0 - Novel modified release formulation - Google Patents

Novel modified release formulation

Info

Publication number
IL157075A0
IL157075A0 IL15707502A IL15707502A IL157075A0 IL 157075 A0 IL157075 A0 IL 157075A0 IL 15707502 A IL15707502 A IL 15707502A IL 15707502 A IL15707502 A IL 15707502A IL 157075 A0 IL157075 A0 IL 157075A0
Authority
IL
Israel
Prior art keywords
matrix former
modified release
release formulation
unit dosage
water
Prior art date
Application number
IL15707502A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0100478A external-priority patent/SE0100478D0/xx
Priority claimed from SE0100477A external-priority patent/SE0100477D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL157075A0 publication Critical patent/IL157075A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Steroid Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15707502A 2001-02-13 2002-02-08 Novel modified release formulation IL157075A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0100478A SE0100478D0 (sv) 2001-02-13 2001-02-13 Novel formulation
SE0100477A SE0100477D0 (sv) 2001-02-13 2001-02-13 Novel formulation
PCT/SE2002/000228 WO2002064121A1 (en) 2001-02-13 2002-02-08 Novel modified released formulation

Publications (1)

Publication Number Publication Date
IL157075A0 true IL157075A0 (en) 2004-02-08

Family

ID=26655389

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15707502A IL157075A0 (en) 2001-02-13 2002-02-08 Novel modified release formulation

Country Status (18)

Country Link
US (3) US20040067252A1 (enExample)
EP (2) EP1361868A1 (enExample)
JP (2) JP2004518708A (enExample)
KR (1) KR20040058103A (enExample)
CN (2) CN1491105A (enExample)
AT (1) ATE324871T1 (enExample)
AU (1) AU2002228579B2 (enExample)
BR (1) BR0206825A (enExample)
CA (2) CA2434542A1 (enExample)
DE (1) DE60211130T2 (enExample)
DK (1) DK1368006T3 (enExample)
ES (1) ES2261643T3 (enExample)
IL (1) IL157075A0 (enExample)
MX (1) MXPA03007092A (enExample)
NO (1) NO20033564L (enExample)
NZ (2) NZ526993A (enExample)
PT (1) PT1368006E (enExample)
WO (2) WO2002064118A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
BR0314787A (pt) * 2002-09-28 2005-07-26 Mcneil Ppc Inc Forma de dosagem de liberação modificada
SE0301904D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab Novel imidazopyridine compound II with therapeutic effect
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2007507425A (ja) * 2003-08-29 2007-03-29 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 胃腸管運動障害を処置するために有用な組成物
WO2005053656A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
WO2005053652A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
AU2004294813A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
SE0303451D0 (sv) * 2003-12-18 2003-12-18 Astrazeneca Ab New compounds
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
HRP20141001T1 (hr) 2006-03-16 2014-12-05 Euro-Celtique S.A. Farmaceutski sferoidi
JP2011516412A (ja) 2008-03-05 2011-05-26 ビカス セラピューティクス，エルエルシー 癌および粘膜炎の治療のための組成物および方法
WO2011000126A1 (zh) * 2009-06-29 2011-01-06 Liu Yu 脂溶性药物组合物、制备方法及其用途
EP2921486B1 (en) 2009-08-07 2017-09-27 American Life Science Pharmaceuticals, Inc. Compositions and methods for treating beta-amyloid related diseases
US20130165880A1 (en) 2010-09-17 2013-06-27 David T. Amos Antimicrobial disposable absorbent articles
WO2012070030A1 (en) * 2010-11-26 2012-05-31 University Of The Witwatersrand, Johannesburg A pharmaceutical composition
CA2859174C (en) 2011-12-12 2019-03-05 Orbis Biosciences, Inc. Sustained release particle formulations
US20130149383A1 (en) * 2011-12-12 2013-06-13 Cory Berkland Sustained release particle formulations of guaifenesin
EP3319595A4 (en) * 2015-06-30 2019-04-03 Kemin Industries, Inc. ENCAPSULATED ACTIVE SUBSTANCES FOR CONTROLLED ENTERAL ACTIVE COMPOSITION
US9889120B2 (en) 2016-01-14 2018-02-13 Vicus Therapeutics, Llc Combination drug therapies for cancer and methods of making and using them
DE102017108054A1 (de) 2017-04-13 2018-10-18 Natura Werk Gebr. Hiller GmbH & Co. KG Essbare Zusammensetzung zur Verdauungsförderung
WO2021142395A1 (en) 2020-01-10 2021-07-15 Consynance Therapeutics, Inc. Therapeutic combinations of drugs and methods of using them
US20250101427A1 (en) 2021-07-22 2025-03-27 The Regents Of The University Of California Compositions and methods for using purified human rna editing enzymes
WO2023184282A1 (en) * 2022-03-30 2023-10-05 Guizhou Sinorda Biomedicine Co., Ltd X842 formulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL248553A (enExample) * 1959-02-18
NL194389C (nl) * 1984-06-14 2002-03-04 Novartis Ag Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4956182A (en) * 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
US5405617A (en) * 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
NZ270439A (en) * 1995-02-02 1996-04-26 Bernard Charles Sherman Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
SE9801526D0 (sv) * 1998-04-29 1998-04-29 Astra Ab New compounds
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions

Also Published As

Publication number Publication date
CA2434835A1 (en) 2002-08-22
DE60211130T2 (de) 2006-11-30
ES2261643T3 (es) 2006-11-16
JP2004518709A (ja) 2004-06-24
EP1368006B1 (en) 2006-05-03
CA2434542A1 (en) 2002-08-22
HK1059740A1 (en) 2004-07-16
CN1491105A (zh) 2004-04-21
NZ526994A (en) 2005-01-28
US20040067256A1 (en) 2004-04-08
BR0206825A (pt) 2004-02-25
US20080118560A1 (en) 2008-05-22
PT1368006E (pt) 2006-08-31
EP1368006A1 (en) 2003-12-10
NZ526993A (en) 2005-01-28
NO20033564D0 (no) 2003-08-12
AU2002228579B2 (en) 2006-07-27
DE60211130D1 (de) 2006-06-08
KR20040058103A (ko) 2004-07-03
MXPA03007092A (es) 2003-11-18
EP1361868A1 (en) 2003-11-19
WO2002064118A1 (en) 2002-08-22
CN1491104A (zh) 2004-04-21
WO2002064121A1 (en) 2002-08-22
US20040067252A1 (en) 2004-04-08
NO20033564L (no) 2003-10-02
JP2004518708A (ja) 2004-06-24
ATE324871T1 (de) 2006-06-15
DK1368006T3 (da) 2006-07-24

Similar Documents

Publication Publication Date Title
IL157075A0 (en) Novel modified release formulation
JP6875407B2 (ja) Ｊａｋキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物
WO2004012700A3 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
EP0378255A3 (en) 2-aminopyrimidinone derivatives
MX2010008711A (es) Composiciones farmaceuticas de entacapona, levopoda y carbidopa, con biodisponibilidad mejorada.
US6833478B2 (en) N,N-dinitramide salts as solubilizing agents for biologically active agents
DK170793B1 (da) Dispergerbar lægemiddelformulering og fremgangsmåde til fremstilling heraf
KR960700070A (ko) 백신 제제(vaccine preparations)
CA2435714C (en) Fenofibrate tablets
KR20110115592A (ko) 피리도피리미디논의 고체 경구 제제
CA2067733C (en) Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure
WO2007061415A1 (en) Pharmaceutical compositions of telmisartan
AU759869B2 (en) Pharmaceutical formulations
KR102861006B1 (ko) 분산성 조성물
CA2364226A1 (en) Controlled-release compositions of betahistine
KR19990023194A (ko) 라세미화 반응에 대하여 안정화된 실란세트론 제제
CA2520813A1 (en) Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists
JPH05310570A (ja) 粒状製剤
TH59782A3 (th) สารผสมของกาแลนแทมีนชนิดปลดปล่อยที่มีการควบคุม
ZA200309710B (en) Pharmaceutical formulation containing an LTB4 antagonist.